Choline Fenofibrate

Product Description
Olon Spa
-comp246698.jpg)
-
IT
-
2015On CPHI since
-
4Certificates
-
1000 - 4999Employees
Company types
Categories
Specifications
Olon Spa
-comp246698.jpg)
-
IT
-
2015On CPHI since
-
4Certificates
-
1000 - 4999Employees
Company types
More Products from Olon Spa (4)
-
Product Active Pharmaceutical Ingredients
OLON is an Italian company world leader in the Active Pharmaceutical Ingredients (APIs) production, using synthetic and biological processes for Generic market as well as in Contract Development and Manufacturing (CDMO).
Always considering human safety and environmental security, OLON handles... -
Product Fermentation
Relying on an experience gained over more than 50 years, OLON represent one of the most extensive know how of microbial fermentation in Europe. The Group, global leader in biomanufacturing, has two Biotechnology Centres located in Italy and is one of the first companies in Italy producing via microbial fe... -
Product Highly Potent Pharmaceutical Principles
Olon relies on one of the most extensive expertise in handling highly potent pharmaceutical principles at global level, has raised the level of containment up to the actual standards and very large scale putting in place a set of primary and secondary containment designed to avoid the active substances di... -
Product Ciclopirox
Olon SpA offers a wide range of products which includes ciclopirox. Therapeutic class: antimicotic. Contact us for more information.
Olon Spa resources (3)
-
News Olon Presenting a Significant Expansion of APIs Pipeline for Olon Group
CPHI WORLDWIDE,
A SIGNIFICANT EXPANSION OF APIs PIPELINE FOR OLON GROUP
-
Video An introduction to Pharmaceuticals in the Environment (PiE) and Anti-Microbial Resistance (AMR)
Pharmaceuticals in the environment (PiE) are an important issue and the subject of increasing focus by the media, governments, NGOs and the wider public. Human and veterinary medicines bring enormous societal benefits, supporting public health and ensuring a safe food supply. One of the unintended but inevitable results of delivering life-changing medicines to patients is that pharmaceutical residues can find their way into the environment. Most are a result of patient and veterinary use and the inappropriate disposal of unused medicines. Unintended release of pharmaceuticals in manufacturing emissions represents a minor yet potentially important environmental source that is controllable and has the potential to be further minimised. This session will provide a practical introduction to the topic aimed at pharmaceutical and healthcare professionals Session in partnership with PSCI (pscinitiative.org) This presentation was originally aired as part of the CPHI Festival of Pharma.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance